The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
Professor Andrew McMichael elected to the US National Academy of Sciences
The National Academy of Sciences (NAS) in the US announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and is considered one of the highest honours that a scientist can receive.
Read moreWhat's new for Oxford Cancer
-
LynchVax Researchers Run Race for Life
19 June 2025
-
Study finds potential path to treatment for an aggressive form of leukaemia
18 June 2025
-
The stellar mission taking on cellular plasticity in bowel cancer
18 June 2025
-
Dr Lennard Lee honoured at the national Cancer Vaccines Awards Ceremony
17 June 2025
-
Action-packed day of immuno-oncology presentations, PPI and networking at this years' annual OCION Symposium!
16 June 2025
CIO News
Professor Andrew McMichael elected to the US National Academy of Sciences
20 May 2025
The National Academy of Sciences (NAS) in the US announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and is considered one of the highest honours that a scientist can receive.
Oxford Immunology Symposium 2025
3 February 2025
The BSI Oxford Immunology Group, in collaboration with the University of Oxford Immunology Network, is pleased to present a one-day showcase of the fantastic immunology research happening across Oxford.
Agonists and Antagonists in Combined Immunotherapies for Cancer
3 February 2025
Prof. Nacho Melero delivers a talk on Immunotherapies in Cancer for GLOBAL IMMUNOTALKS
Reversing resistance to cancer immune therapy with antibodies
30 January 2025
A new study led by Professor Ignacio Melero of NDM's Centre for Immuno-oncology and the University of Navarra and has highlighted a way to combat resistance to cancer immunotherapy in solid tumours by using antibodies that target GDF-15 protein.
Latest publications
-
Atom-level mechanism of tapasin-independent peptide editing by Major Histocompatibility Complex class I molecules
Preprint
Turner S. et al, (2025)
-
Strict advantage of complex quantum theory in a communication task
Journal article
Elliott TJ., (2025), Physical Review A, 111
-
Antigen-presenting mast cells are new players in breast cancer immunotherapy.
Journal article
Luri-Rey C. et al, (2025), Nature medicine
-
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.
Journal article
Lee CY. et al, (2025), Cancer immunology research
-
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Journal article
Ruiz-Fernández de Córdoba B. et al, (2025), Signal transduction and targeted therapy, 10
-
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
Journal article
Alsina M. et al, (2025), Clin Cancer Res
-
Supplemental Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplementary Figure S1 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 5 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 3 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 4 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Journal article
Skolariki A. et al, (2025), Mol Oncol
-
Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.
Journal article
Vadibeler S. et al, (2025), Matrix biology : journal of the International Society for Matrix Biology
-
Immunocytokines and cytokine neutralization for cancer immunotherapy
Journal article
Berraondo P. et al, (2025), Trends in Cancer
-
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Journal article
Heras-Murillo I. et al, (2025), Nature Communications, 16
Oxford Talks
-
Friday, 04 July 2025, 9.15am to 10.15am
Speakers: Shamsideen Yusuf, Dana Costigan
Venue: MRC Weatherall Institute of Molecular Medicine, Headington OX3 9DS
-
Friday, 04 July 2025, 11am to 3pm
Venue: Radcliffe Humanities, Woodstock Road OX2 6GG
-
Friday, 04 July 2025, 11am to 12pm
Speakers: Dr Ludovica Griffanti
-
Friday, 04 July 2025, 3pm to 4pm
Speakers: Associate Professor Hagen Tilgner
Venue: IMS-Tetsuya Nakamura Building, Roosevelt Dr, Headington OX3 7TY
-
Friday, 04 July 2025, 4pm to 5.30pm
Venue: Dyson Perrins Building, off South Parks Road OX1 3QY